Nashiah AI Agency Platform: Building an Agentic AI Workforce for Pharma Commercial Operations

Pharmaceutical and life sciences marketing agencies are expected to deliver increasingly sophisticated digital experiences, coordinated omnichannel campaigns, measurable commercial insights, and compliant content. Meeting these demands requires a combination of creative expertise, specialized technology, data intelligence, and reliable operational support. Nashiah, a division of ISmile Technologies focused on pharma, healthcare, and life sciences, provides a technology and delivery platform designed to help agencies expand their capabilities, execute client work faster, and develop new recurring revenue opportunities.

The Nashiah AI Agency Platform introduces an agentic AI workforce for pharma commercial operations. Rather than treating AI as an isolated tool, the platform brings together specialized agents, reusable workflows, data platforms, application development, and managed services. The approach enables agencies to extend their delivery capacity while retaining ownership of client relationships, commercial strategy, and creative direction. Nashiah provides the technology, engineering, data, and ongoing operations needed to bring agency-led ideas into production.

One of the primary opportunities is AI-enabled digital content production. Pharmaceutical agencies regularly develop websites, landing pages, digital banners, approved email templates, interactive visual aids, and CLM presentations. These deliverables require coordination between creative teams, brand guidelines, approved assets, and validation processes. An AI-supported production workflow can help organize these inputs, accelerate development, and support pre-release validation while keeping agency teams responsible for creative direction and final approval.

Within the platform, Alex represents the Digital and Content Production Agent. As presented in the Nashiah materials, Alex supports the production of digital banners, approved email templates, interactive visual aids, websites and microsites, and CLM presentations, alongside pre-release validation. The associated workflow can connect brand and template repositories, existing design references, supported design tools, and approved image-generation capabilities. These integrations help teams reuse brand assets, apply consistent design rules, and reduce repetitive production work.

Content production in pharmaceutical environments also requires attention to medical, legal, and regulatory requirements. Nashiah describes an AI-enabled pre-MLR review capability that extracts claims, matches them against approved claims and references, validates supporting evidence, flags potential regulatory risks, and checks consistency with brand and editorial guidelines. The resulting pre-flight report can identify compliant, near-match, and potentially non-compliant claims, suggest revisions for risky or unsupported language, and provide linked references for reviewer validation.

The pre-MLR workflow is intended to help teams identify issues before formal medical, legal, and regulatory review begins. By introducing structured checks earlier, organizations can reduce repetitive manual review effort, improve consistency across assets, and prepare materials more efficiently. AI-generated findings remain inputs for human review; authorized reviewers must verify claims, assess context, resolve flagged issues, and retain responsibility for approval and compliance decisions.

Audience intelligence is another capability described in the platform. SynthAudience is presented as an AI-driven audience intelligence solution that helps marketing and brand teams explore how patients, healthcare professionals, and caregivers may respond to campaign messages and educational materials. Teams can configure a brand, select an audience and persona, provide campaign content, review simulated feedback, compare responses, and refine messaging before launch.

This simulation-based approach can help teams explore messaging alternatives, identify potential communication gaps, and align stakeholders before committing to a campaign. The platform is designed to support multiple brands and therapeutic areas while making early-stage message exploration more accessible. Simulated audience feedback is directional and should complement, rather than replace, appropriate research, clinical evidence, regulatory review, and real-world audience validation.

Nashiah also supports commercial intelligence through data integration and analytics. Pharmaceutical marketing teams often work across media platforms, web analytics, CRM systems, and other operational data sources. When these systems remain disconnected, teams can struggle to establish a consistent view of campaign performance, understand healthcare professional engagement, compare brand results, and identify the factors influencing changes in commercial outcomes.

The Data Intelligence Platform addresses this challenge by bringing data from sources such as Google Ads, Meta, Campaign Manager 360, Display & Video 360, Google Analytics 4, CRM systems, and other marketing platforms into a unified analytics environment. The architecture described in the presentation includes data ingestion and validation, Azure Data Lake and Synapse Analytics for lakehouse storage and analytics, AI-powered processing, and Power BI dashboards or chat interfaces for reporting and natural-language queries.

A unified data foundation can support cross-channel attribution, healthcare professional engagement tracking, self-service dashboards, automated reporting, and AI-generated insights. Brand teams can access relevant performance information with less dependence on manual reporting processes, while standardized metrics and data quality controls help maintain consistency. The presentation reports a 60% reduction in manual reporting time for the described Data Intelligence Platform capability; this figure relates to the presented solution and should not be interpreted as a guaranteed result for every implementation.

Beyond analytics, the platform supports omnichannel orchestration and commercial workflow automation. Its capabilities include connecting marketing technology systems, coordinating approved content across channels, automating customer journeys, and supporting AI-powered next-best-action recommendations. By connecting planning, insight, and execution, these workflows can help commercial teams make more coordinated decisions and deliver more consistent experiences across channels.

The broader Nashiah capability stack includes AI applications and innovation, machine learning and data platforms, integrated development, omnichannel orchestration, hosting and managed services, technology leadership, quality assurance, and Veeva platform enablement. This includes services associated with Veeva PromoMats, Veeva CRM, Veeva Compass, Veeva Claims, and Veeva Network, as well as CRM migration and optimization. Together, these capabilities support agencies and pharmaceutical organizations across the development, integration, operation, and validation of commercial technology solutions.

The underlying Agient approach emphasizes workflow design before technology implementation. Its reusable foundations include document intelligence, workflow orchestration, human approvals, audit trails, knowledge retrieval, integration frameworks, and agent coordination patterns. The approach begins by simplifying existing processes, removing unnecessary handoffs, defining approval boundaries, establishing evidence requirements, and applying reusable workflow accelerators. The presentation also describes deployment in the agency's cloud, with the agency owning the code, data pipelines, and models.

Governance is central to the proposed agentic AI workforce. The platform's stated principles include human approval for decisions, traceability of figures to their sources, role-based access, action logging, and testing before changes are introduced. These controls are particularly important in pharmaceutical commercial operations, where approved content, customer data, claims, and regulatory processes require careful handling. Clear accountability and controlled workflows help organizations adopt automation without transferring critical decisions entirely to AI systems.

For agencies, the business opportunity extends beyond improving the efficiency of existing services. By combining content production, pre-MLR review support, audience simulation, commercial analytics, omnichannel orchestration, and managed digital operations, agencies can expand their service portfolios and deliver additional technology-enabled offerings. Nashiah's role is to provide the technical and operational foundation, allowing agencies to focus on client relationships, strategic direction, and creative execution.

A practical starting point is to select one workflow with a clear business need, such as digital asset production, pre-MLR review preparation, or monthly marketing reporting. Teams can map the current process, identify repetitive tasks and unnecessary handoffs, define evidence and approval requirements, connect the necessary data and systems, and test the workflow under controlled conditions. Measuring review effort, production turnaround time, reporting preparation time, quality, and user adoption can help determine where expansion is justified.

Nashiah's AI Agency Platform brings together specialized AI agents, reusable workflows, commercial data intelligence, and managed technology capabilities to support the evolving needs of pharmaceutical marketing agencies. By combining automation with human oversight and governed execution, the platform provides a foundation for scaling digital delivery, strengthening commercial intelligence, and introducing new AI-enabled services across pharma and life sciences.